Explore

Rapid Read Rapid Read
Apotex Gains Health Canada Approval for Generic Ozempic, Expanding Access to Diabetes Treatment

Apotex Gains Health Canada Approval for Generic Ozempic, Expanding Access to Diabetes Treatment

Apotex Inc., a Canadian-based global health company, has received approval from Health Canada for Apo-Semaglutide Injection, a generic equivalent of Ozempic (semaglutide injection). This marks the first time a Canadian pharmaceutical company has been authorized to produce a generic version of Ozempic, a medication used for the treatment of type 2 diabetes. The approval includes two prefilled pen formats, offering doses of 0.25 mg, 0.5 mg, and 1 mg. Apotex's move is aimed at providing a high-quality, affordable alternative to Canadians, reinforcing its commitment to improving access to essential medicines. The company has partnered with Orbicular Pharmaceutical Technologies for the development of this product.
Trendline Trendline
FDA Approves LANGLARA as Interchangeable Biosimilar for Diabetes Treatment

FDA Approves LANGLARA as Interchangeable Biosimilar for Diabetes Treatment

FDA Approves LANGLARA as Interchangeable Biosimilar for Diabetes Treatment
Trendline Trendline
FDA Approves Lannett's LANGLARA as Interchangeable Biosimilar for Diabetes Treatment

FDA Approves Lannett's LANGLARA as Interchangeable Biosimilar for Diabetes Treatment

FDA Approves Lannett's LANGLARA as Interchangeable Biosimilar for Diabetes Treatment
Trendline Trendline
FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients

FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients

FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients
Trendline Trendline
North America Biotechnology Market Projected to Reach USD 2168.91 Billion by 2035

North America Biotechnology Market Projected to Reach USD 2168.91 Billion by 2035

North America Biotechnology Market Projected to Reach USD 2168.91 Billion by 2035
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
NRx Pharmaceuticals Begins U.S. Manufacturing of Preservative-Free Ketamine

NRx Pharmaceuticals Begins U.S. Manufacturing of Preservative-Free Ketamine

NRx Pharmaceuticals Begins U.S. Manufacturing of Preservative-Free Ketamine
Rapid Read Rapid Read
Cochrane Review Finds Alzheimer's Drugs Ineffective and Risky for Brain Health

Cochrane Review Finds Alzheimer's Drugs Ineffective and Risky for Brain Health

A comprehensive Cochrane review has concluded that drugs targeting amyloid beta proteins in the brain do not provide significant benefits for Alzheimer's patients and may increase the risk of brain swelling and bleeding. The review analyzed 17 clinical trials with 20,342 participants, focusing on individuals with mild cognitive impairment or early-stage Alzheimer's dementia. Despite the long-held belief that removing amyloid deposits could slow or prevent Alzheimer's, the study found that the impact of these drugs on memory decline and dementia severity was negligible. Lead author Francesco Nonino, a neurologist and epidemiologist, emphasized that while early trials showed statistically significant results, they did not translate into meaningful clinical benefits. Additionally, the review highlighted safety concerns, noting that anti-amyloid drugs were associated with a higher likelihood of brain swelling and bleeding, although these changes were often asymptomatic and detected only through brain scans.
Trendline Trendline
Advancements in AI and Genomics Propel Personalized Medicine Market to USD 1,397.63 Billion by 2035

Advancements in AI and Genomics Propel Personalized Medicine Market to USD 1,397.63 Billion by 2035

Advancements in AI and Genomics Propel Personalized Medicine Market to USD 1,397.63 Billion by 2035
Rapid Read Rapid Read
Amarox Recalls Sertraline Batch Due to Packaging Error Involving Antidepressants

Amarox Recalls Sertraline Batch Due to Packaging Error Involving Antidepressants

Amarox, a subsidiary of the Indian drugmaker Hetero Group, is recalling a batch of sertraline after mistakenly packaging it with a blister strip of another antidepressant, citalopram. The UK Medicines and Healthcare products Regulatory Agency (MHRA) announced the recall after a patient complaint revealed the error. The recall affects 100 mg film-coated tablets of sertraline, a selective serotonin reuptake inhibitor (SSRI). The error occurred during secondary packaging at the manufacturing facility. Healthcare professionals are advised to quarantine remaining stock and return it to suppliers. Pharmacists are instructed to contact patients who received the recalled product, especially those who received it in the past 28 days. The MHRA warns that concurrent exposure to two SSRIs may increase serotonergic effects, posing risks to patients, particularly those with pre-existing cardiac conditions or those taking other serotonergic medications.
Rapid Read Rapid Read
Health Canada Approves Generic Versions of Ozempic, Impacting Drug Costs

Health Canada Approves Generic Versions of Ozempic, Impacting Drug Costs

Health Canada has approved two generic versions of the diabetes drug Ozempic, marking Canada as the first G7 country to do so. The patent for Ozempic, originally held by Novo Nordisk, expired in early January, allowing for the introduction of generic alternatives. The approved generics are from Dr. Reddy’s Laboratories and Canadian-based Apotex. These generic versions are expected to be significantly cheaper, potentially reducing costs for patients who currently pay high out-of-pocket expenses for the medication. Health Canada assures that these generics are pharmaceutically equivalent to the brand-name drug, maintaining safety and efficacy standards.
Rapid Read Rapid Read
Health Canada Approves Generic Versions of Ozempic, Paving Way for Cost Savings

Health Canada Approves Generic Versions of Ozempic, Paving Way for Cost Savings

Health Canada has approved two generic versions of the diabetes drug Ozempic, making Canada the first G7 country to do so. The approval follows the expiration of Ozempic's patent in Canada, allowing for the introduction of generic alternatives. The approved generics, produced by Dr. Reddy’s Laboratories and Apotex, are expected to offer a more affordable option for patients. Generic medications typically cost 45 to 90 percent less than their brand-name counterparts, which could significantly reduce expenses for Canadians who rely on this medication for managing type 2 diabetes and weight loss.